Lloyd Haskell

4.3k citations

69 papers · 2.1k indexed · 2 hit papers · h-index 22

Impact in

Internal Medicine top 0.2%
- Venous Thromboembolism Diagnosis and Management
Cardiology and Cardiovascular Medicine top 1%
- Atrial Fibrillation Management and Outcomes
- Antiplatelet Therapy and Cardiovascular Diseases
- Acute Myocardial Infarction Research

Papers in ⓘ

Internal Medicine 26
- Venous Thromboembolism Diagnosis and Management 26
Cardiology and Cardiovascular Medicine 42
- Atrial Fibrillation Management and Outcomes 19
- Antiplatelet Therapy and Cardiovascular Diseases 14
- Blood Pressure and Hypertension Studies 6
- Acute Myocardial Infarction Research 5

Co-authors: Theodore E. Spiro (9 shared papers)Alex C. Spyropoulos (7 shared papers)Geno J. Merli (6 shared papers)Harry R. Büller (6 shared papers)Dayi Hu (6 shared papers)Victor F. Tapson (6 shared papers)Alexandre Mebazaa (6 shared papers)Sebastian Schellong (5 shared papers)
Journals: Journal of the American College of Cardiology (7 papers)Circulation (6 papers)Journal of the American Heart Association (3 papers)Journal of Thrombosis and Haemostasis (3 papers)The Journal of Clinical Pharmacology (3 papers)
Partner nations: United States Germany Canada

In The Last Decade

Lloyd Haskell

60 papers receiving 2.1k citations

Hit Papers

align trajectories log scale

Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism 2017 · 492 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2017 New England Journal of Medicine
2013 New England Journal of Medicine

Peers

Countries citing papers authored by Lloyd Haskell

Since Specialization

Citations

This map shows the geographic impact of Lloyd Haskell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lloyd Haskell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lloyd Haskell more than expected).

Fields of papers citing papers by Lloyd Haskell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lloyd Haskell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lloyd Haskell. The network helps show where Lloyd Haskell may publish in the future.

Co-authors

The 25 scholars most cited alongside Lloyd Haskell, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Lloyd Haskell Line = papers co-authored together Lloyd Haskell links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 69 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism New England Journal of Medicine ·Jeffrey I. Weitz, Anthonie W.A. Lensing, Martin H. Prins, Rupert Bauersachs, Jan Beyer‐Westendorf, Henri Bounameaux, Timothy Brighton, Alexander T. Cohen, Bruce L. Davidson, Hervé Decousus, Maria Cecília S. Freitas, Gerlind Holberg, Ajay K. Kakkar, Lloyd Haskell, Bonno van Bellen, Ákos F. Pap, Scott D. Berkowitz, Peter Verhamme, Philip S. Wells, Paolo Prandoni Hit paper breakdown →	2017	492
2	Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients New England Journal of Medicine ·Alexander T Cohen, Theodore E. Spiro, Harry R. Büller, Lloyd Haskell, Dayi Hu, Russell D. Hull, Alexandre Mebazaa, Geno J. Merli, Sebastian Schellong, Alex C. Spyropoulos, Victor F. Tapson Hit paper breakdown →	2013	436
3	Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: A dose-ranging study Gastroenterology ·Stephen B. Hanauer, Malcolm Robinson, Ronald E. Pruitt, Audrey J. Lazenby, Tore Persson, Lars‐Göran Nilsson, Karen Walton–Bowen, Lloyd Haskell, Jeffrey G. Levine	1998	129
4	Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol Journal of Thrombosis and Thrombolysis ·Alexander Thomas Cohen, Theodore E. Spiro, Harry R. Büller, Lloyd Haskell, Dayi Hu, Russell D. Hull, Alexandre Mebazaa, Geno J. Merli, Sebastian Schellong, Alex C. Spyropoulos, Victor F. Tapson	2011	91
5	D‐dimer as a predictor of venous thromboembolism in acutely ill, hospitalized patients: a subanalysis of the randomized controlled MAGELLAN trial Journal of Thrombosis and Haemostasis ·Alexander T. Cohen, Theodore E. Spiro, Alex C. Spyropoulos, Yoriko DeSanctis, Martin Homering, Harry R. Büller, Lloyd Haskell, Dayi Hu, R. Hull, Alexandre Mebazaa, Geno J. Merli, Sebastian Schellong, Victor F. Tapson, Paul Burton	2014	90
6	Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD) American Heart Journal ·Warren H. Capell, Marc P. Bonaca, Mark R. Nehler, Edmond Chen, John M. Kittelson, Sonia S. Anand, Scott D. Berkowitz, E. Sebastian Debus, Fabrizio Fanelli, Lloyd Haskell, Manesh R. Patel, Rupert Bauersachs, William R. Hiatt	2018	84
7	Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization Circulation ·William R. Hiatt, Marc P. Bonaca, Manesh R. Patel, Mark R. Nehler, E. Sebastian Debus, Sonia S. Anand, Warren H. Capell, Taylor Brackin, Nicole Jaeger, Connie N. Hess, Ákos F. Pap, Scott D. Berkowitz, Eva Muehlhofer, Lloyd Haskell, David Brasil, Juraj Maďarič, Henrik Sillesen, David Szalay, Rupert Bauersachs	2020	70
8	The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE Thrombosis and Haemostasis ·Alex C. Spyropoulos, Julie Zrubek, Walter Ageno, Gregory W. Albers, C. Gregory Elliott, Jonathan L. Halperin, Lloyd Haskell, William R. Hiatt, Gregory A. Maynard, Gary Peters, Theodore E. Spiro, Philippe Gabríel Steg, Eun Young Suh, Jeffrey I. Weitz, Gary E. Raskob	2016	58
9	Polyarteritis nodosa and familial Mediterranean fever: a report of 2 cases and review of the literature. PubMed ·Michael Glikson, E. Galun, M Schlesinger, Daniel Cohen, Lloyd Haskell, Alan Rubinow, M Eliakim	1989	56
10	V1/V2 Vasopressin receptor antagonism potentiates the renoprotection of renin–angiotensin system inhibition in rats with renal mass reduction Kidney International ·Norberto Perico, Carla Zoja, Daniela Corna, Daniela Rottoli, Flavio Gaspari, Lloyd Haskell, Giuseppe Remuzzi	2009	51
11	Predicting the Risk of Venous Thromboembolism in Patients Hospitalized With Heart Failure Circulation ·Alexandre Mebazaa, Theodore E. Spiro, Harry R. Büller, Lloyd Haskell, Dayi Hu, Russell D. Hull, Geno J. Merli, Sebastian Schellong, Alex C. Spyropoulos, Victor F. Tapson, Yoriko De Sanctis, Alexander T. Cohen	2014	43
12	An open‐label study to estimate the effect of steady‐state erythromycin on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban in subjects with renal impairment and normal renal function The Journal of Clinical Pharmacology ·Kenneth Todd Moore, Seema Vaidyanathan, Jaya Natarajan, Jay Ariyawansa, Lloyd Haskell, K. C. Turner	2014	42
13	Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program Journal of Medical Economics ·Brahim Bookhart, Lloyd Haskell, Luke Bamber, Maria Wang, Jeff Schein, Samir H. Mody	2014	37
14	Metoprolol CR/XL in patients with heart failure: A pilot study examining the tolerability, safety, and effect on left ventricular ejection fraction American Heart Journal ·Sidney Goldstein, Harold L. Kennedy, Christian Hall, Jeffrey L. Anderson, Mihai Gheorghiade, Stephen S. Gottlieb, Mariell Jessup, Ronald P. Karlsberg, Gary Friday, Lloyd Haskell	1999	36
15	Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism Thrombosis and Haemostasis ·Rupert Bauersachs, Jan Beyer‐Westendorf, Henri Bounameaux, Timothy Brighton, Alexander Cohen, Bruce L. Davidson, Gerlind Holberg, Ajay K. Kakkar, Anthonie W.A. Lensing, Martin H. Prins, Lloyd Haskell, Bonno van Bellen, Peter Verhamme, Philip Wells, Paolo Prandoni, Jeffrey Weitz, (unknown)	2015	35
16	Possible Genetic Predisposition to Idiopathic Focal Segmental Glomerulosclerosis American Journal of Kidney Diseases ·Daniel Glicklich, Lloyd Haskell, David Senitzer, Robert A. Weiss	1988	35
17	Case Report: Disseminated Toxoplasmosis Presenting as Symptomatic Orchitis and Nephrotic Syndrome The American Journal of the Medical Sciences ·Lloyd Haskell, Mary Jean Fusco, Luz Ares, Bella Sublay	1989	29
18	Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PAD Trial Journal of the American College of Cardiology ·Rupert Bauersachs, Michael Szarek, Marianne Brodmann, Ivan Gudz, E. Sebastian Debus, Mark R. Nehler, Sonia S. Anand, Manesh R. Patel, Connie N. Hess, Warren H. Capell, Kevin Rogers, Eva Muehlhofer, Lloyd Haskell, Scott D. Berkowitz, William R. Hiatt, Marc P. Bonaca	2021	28
19	Rivaroxaban for thromboprophylaxis among patients recently hospitalized for acute infectious diseases: a subgroup analysis of the MAGELLAN study Journal of Thrombosis and Haemostasis ·Kevin P. Cohoon, Yoriko De Sanctis, Lloyd Haskell, Robert D. McBane, Theodore E. Spiro	2018	22
20	HLA Associations in Heroin-Associated Nephropathy American Journal of Kidney Diseases ·Lloyd Haskell, Daniel Glicklich, David Senitzer	1988	22

About Lloyd Haskell

Lloyd Haskell is a scholar working on Internal Medicine, Cardiology and Cardiovascular Medicine, Surgery, Anesthesiology and Pain Medicine and Hematology, having authored 69 papers that have together received 2.1k indexed citations. Recurring topics across this work include Venous Thromboembolism Diagnosis and Management (26 papers), Peripheral Artery Disease Management (24 papers), Atrial Fibrillation Management and Outcomes (19 papers), Antiplatelet Therapy and Cardiovascular Diseases (14 papers), Blood Pressure and Hypertension Studies (6 papers), Blood Coagulation and Thrombosis Mechanisms (5 papers), Acute Myocardial Infarction Research (5 papers) and Diagnosis and Treatment of Venous Diseases (5 papers). The work is most often cited by research in Internal Medicine (1.3k citations), Cardiology and Cardiovascular Medicine (1.3k citations), Hematology (247 citations), Emergency Medical Services (142 citations) and Nephrology (112 citations). Lloyd Haskell has collaborated with scholars based in United States, Germany and Canada. Frequent co-authors include Theodore E. Spiro, Alex C. Spyropoulos, Geno J. Merli, Harry R. Büller, Dayi Hu, Victor F. Tapson, Alexandre Mebazaa, Sebastian Schellong, Russell D. Hull and Rupert Bauersachs. Their work appears in journals such as Journal of the American College of Cardiology, Circulation, Journal of the American Heart Association, Journal of Thrombosis and Haemostasis and The Journal of Clinical Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact